Closed · HT9425-23-S-CRRP · CFDA 12.420 · Discretionary
DoD Combat Readiness - Translational Research Award
Federal grant opportunity posted by Dept. of the Army -- USAMRAA, cataloged on Grants.gov.
- Varies
- Award range
- Closed
- Status
- July 20, 2023
- Close date
- 4
- Expected awards
The verdict
DoD Combat Readiness - Translational Research Award is a closed discretionary listing from Dept. of the Army -- USAMRAA that offered Varies by applicant across 4 expected awards. Future funding cycles may be published under the same CFDA number.
- Varies
- award range
- Closed
- application status
- 4
- expected awards
- 12.420
- CFDA program
Opportunity snapshot. This Grants.gov announcement - DoD Combat Readiness - Translational Research Award - is cataloged under number HT9425-23-S-CRRP and tied to CFDA assistance listing 12.420, posted by Dept. of the Army -- USAMRAA. Grants.gov currently shows the opportunity as closed, first posted on May 17, 2023. The funding category is Discretionary, delivered as a procurement contract.
Award economics. The award range on file is Varies by applicant. The agency has projected $4.4 million in total estimated funding for this announcement. It expects to issue 4 awards. If the agency funds the expected 4 awards from the $4.4 million estimated pool, the average award works out to roughly $1.1 million. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on July 20, 2023. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Varies by applicant
Close Date
July 20, 2023
Posted
May 17, 2023
Est. Total Funding
$4,400,000
Expected Awards
4
Instrument
Procurement Contract
Description
The CRRP seeks to increase pre-hospital survivability of the Warfighter by enabling individuals, of varying expertise, to address casualties of the battlespace and closer to the point of injury. The intent of the FY23 CRRP TRA is to support high-impact translational research that will accelerate innovative ideas into clinical applications, including health care products, technologies, and/or practice guidelines. Research funded under this award mechanism will be hypothesis-driven, high-impact applied research that is relevant to active-duty Service Members, Veterans, other military beneficiaries, and the American public.Applicants may leverage existing resources in translational research to address high-impact research ideas or unmet needs to enable the delivery of life-saving care to the Warfighter during prolonged and en route care in austere and combat environments. For this award mechanism, the definition of “leveraging” is as follows: An investigator basing a research project on existing resources in order to amplify potential gains in knowledge or accelerate technical maturity. Research of interest may include knowledge products, “knowledge resulting from research with the potential to improve individual or public health,”2 and solutions that can accelerate the introduction of military-relevant health products or technologies into clinical and/or operational use. Projects should take into consideration the varied expertise levels of targeted medical providers, available resources, and the possible diverse environmental conditions in combat situations. Proposal/application submissions are encouraged to include characteristics relevant to military use in the pre-hospital, combat operational setting. Submissions that propose solutions to advance civilian trauma care are not precluded, since civilian trauma and trauma care in the military are mutually influential and may be co-occurring in certain situations.Impact is a key component of this award mechanism. The potential impact of the research, both short term and long term, in addressing the FY23 CRRP Focus Area(s) should be clearly described. Successful high-impact research should lead to the rapid development and translation of applicable advances for improving medical readiness, mitigating fatalities, optimally treating life-threatening injuries, and promoting positive long-term outcomes for military health and medicine, as well as the general public.Key aspects of the CRRP Translational Research Award Mechanism:• This BAA may be used to support applied, preclinical, and/or clinical research.• Clinical trials for U.S. Food and Drug Administration (FDA) licensure of drugs and definitive/pivotal testing for device clearance by the FDA will NOT be permitted under this BAA.• Preliminary data are required: Inclusion of preliminary data relevant to the proposed study is required.• Statistical Analysis and Data Management Plans: The application should include a clearly articulated statistical analysis plan; a power analysis reflecting sample size projections that will answer the objectives of the study; and a data management plan and use of an appropriate database to safeguard and maintain the integrity of the data.Applications in response to this BAA may not be used to support fundamental basic research. For this BAA, basic research is defined as research directed toward greater knowledge or understanding of the fundamental aspects of phenomena and of observable facts without specific applications toward process or products in mind. Applied and preclinical research, including animal studies, that is already supported by substantial preliminary or published data, and is designed to validate clinical translation, is appropriate for this award mechanism.Funding from this BAA may not be used to support studies requiring an exception from informed consent (EFIC).Clinical research encompasses research with patient samples, data, and interaction with patients that may or may not be considered a clinical trial. For the purposes of this funding opportunity, research that meets the definition of a clinical trial is distinct from clinical research. Clinical research is observational in nature and includes: (1) Research that does not seek to evaluate the effects of interventions. Research conducted with human subjects (or on material of human origin such as data, tissues, specimens, and cognitive phenomena) for which an investigator (or colleague) directly interacts with human subjects, but does not seek to assess the effects of an intervention, qualifies as clinical research. Patient-oriented research may include but is not limited to: (a) mechanisms of human disease, (b) diagnostic or detection studies (e.g., biomarker or imaging), (c) health disparity studies, and (d) development of new technologies. (2) Epidemiologic and behavioral studies that do not seek to study the safety, effectiveness, and/or efficacy outcomes of an intervention. (3) Outcomes research and health services research that do not fit under the definition of clinical trial. Excluded from the definition of clinical research are in vitro studies that utilize human tissues that cannot be linked to a living individual. Note: Studies that meet the requirements for exemption under §46.104(d)(4) of the Common Rule are not considered clinical research as defined by CDMRP. Exemption category 4 refers to secondary research for which consent is not required.A clinical trial is defined as a research study in which one or more human subjects are prospectively assigned to one or more interventions (which may include a placebo or another control) to evaluate the effects of the interventions on biomedical or behavioral health-related outcomes. Clinical trials are not allowed under this funding opportunity announcement.Studies that do not seek to measure safety, effectiveness, and/or efficacy outcome(s) of an intervention are not considered clinical trials.The period of performance of the CRRP TRA will be 2 years. The anticipated total costs budgeted for an FY23 CRRP TRA should not exceed $1.1M.Refer to Section II.D.6, Funding Restrictions, for detailed funding information.Awards will be made no later than September 30, 2024. For additional information refer to Section II.F.1, Federal Award Notices.The CDMRP expects to allot approximately $4.4M to fund approximately four CRRP Translational Research Award proposals/applications. Funding of proposals/applications received is contingent upon the availability of federal funds for this program as well as the number of proposals/applications received, the quality and merit of the proposals/applications as evaluated by scientific and programmatic review, and the requirements of the government. Funds to be obligated on any award resulting from this funding opportunity will be available for use for a limited time period based on the fiscal year of the funds. It is anticipated that awards made from this FY23 funding opportunity will be funded with FY23 funds, which will expire for use on September 30, 2029.Proposals/applications received in response to both the extramural FY23 CRRP TRA BAA and the intramural program announcement will be evaluated and considered for funding. The government reserves the right to fund any combination of extramural and/or intramural proposals/applications.The USAMRDC executes its extramural research program primarily through the awarding of contracts, assistance agreements (grants and cooperative agreements), and Other Transaction Agreements (OTAs). The type of instrument used to reflect the business relationship between the organization and the government is at the discretion of the government, in accordance with the Federal Grant and Cooperative Agreement Act of 1977, as amended, 31 USC 6301-6308, which provides the legal criteria to select a procurement contract or an assistance agreement.An assistance agreement (grant or cooperative agreement) is appropriate when the federal government transfers a “thing of value” to a “state, local government,” or “other recipient” to carry out a public purpose of support or stimulation authorized by a law of the United States, instead of acquiring property or service for the direct benefit and use of the U.S. government. An assistance agreement can take the form of a grant or cooperative agreement. If “no substantial involvement” on the part of the funding agency is anticipated, a grant award will be made (31 USC 6304).Conversely, if substantial involvement on the part of the funding agency is anticipated, a cooperative agreement will be made (31 USC 6305) and the award will identify the specific substantial involvement. Substantial involvement may include collaboration, participation, or intervention in the research to be performed under the award.A contract is required when the principal purpose of the instrument is to acquire property or services for the direct benefit or use of the U.S. government.An Other Transaction (OT) will also be considered as a vehicle for award under this BAA, in accordance with 10 USC 4021 and 10 USC 4022. The OT authorities were created to give the DOD the flexibility necessary to adopt and incorporate business practices that reflect commercial industry standards and best practices into its award instruments. When leveraged appropriately, OTs provide the government with access to state-of-the-art technology solutions from traditional and non-traditional defense contractors (NDCs), through a multitude of potential teaming arrangements tailored to the particular project and the needs of the participants. OTs can help to foster new relationships and practices involving traditional and NDCs, especially those that may not be interested in entering into FAR-based contracts with the government; broaden the industrial base available to government; support dual-use projects; encourage f
Eligibility
Grants.gov lists this opportunity under eligibility category code 99. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Agency Contact
CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from Dept. of the Army -- USAMRAA
BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical and Human Performance Research and Development Department of Defense
DOD Defense Health Agency (DHA) Research & Development FY23-FY27 BROAD AGENCY ANNOUNCEMENT for Extramural Medical Research
Department of Defense HIV/AIDS Prevention Program
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |